Interested participants are invited to register in advance by clicking here.

During the webinar, Foresight executives and customers will discuss the Company’s progress in developing and distributing innovative new technologies for the automotive industry. Attendees will learn how new solutions from Foresight are gaining traction in different regional markets and are solving challenging problems for customers like Hitachi Astemo Americas and SUNWAY-AI. This webinar will provide worthwhile insights into how Foresight has begun to commercialize its advanced technologies globally.

Speakers and Agenda:

Recent Company Developments in the Chinese Market and Long-Term Strategy

Speaker: Oren Bar-On, VP Global Operations and Business Strategy at Foresight

How Multispectral Vision Delivered Key Benefits for SUNWAY

Speaker: Li Chong, CEO at SUNWAY-AI

Turning the Corner on Foresight’s Global Commercialization

Speaker: Doron Cohadier, VP Business Development at Foresight

The Future of Stereo for Automotive Technology

Speaker: Kosuke Sakata, Lead engineer of Silicon Valley Advanced Research Office at Hitachi Astemo Americas

Q&A Session

To register (free registration) click here

For more information regarding this event, please visit Foresight’s Investor Relations page here.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the Company’s wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (3D) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.

Dagi Ben-Noon is the Co-Founder of Inspira Technologies. Dagi worked as a Director at Nano Dimension Ltd. between August 25, 2014, through April 24, 2017; he filled in as the Company’s Chief Operating Officer.

A brief overview of Nano Dimension (Nasdaq, TASE: NNDM)

Nano Dimension Ltd. specializes in 3D printing. The company was established in 2012 by Amit Dror and Simon Anthony-Fried and is located in Ness Ziona, Israel. The business focuses on 3D printed electronics research and development, including the creation of a printer for multilayer printed circuit boards and inks based on nanotechnology.

 It provides sophisticated devices for the creation of additively produced electronics.  The DragonFly Pro System, inks for printed electronics, and multi-material isdesigned of complex electronics.

Nano Dimension connects printed circuit boards (PCBs) with semiconductor Integrated Circuits (SICs). The machines deliver unrivaled performance by conserving conductive and dielectric materials and assembling in-situ capacitors, radio wires, coils, transformers, and electromechanical parts.

Future of NNDM and Inspira:

Inspira uses a multi-step strategy to bring its ART system to market. Inspira intends to bring the ART system to the market with the new intent of use by 2023. One will first submit a 510k to one of their components at the end of 2022, and they expect to offer Inspira’s integrated system 510k at the end of that year since they have two parallel routes linked. Inspira is trying to create agreements with strategic partners and globally ranking health facilities to give endorsement and future clinical acceptance of their ART system as part of its plan to achieve this goal and obtain regulatory clearances.

A passionate and professional team with an original vision and a proven track record of execution success is working under IINN. A highly seasoned management team with a successful track record. Prof. Benad Goldwasser, the chairman, has ten exits to his name, and Dagi Ben-Noon, one of the Co-Founders, is a social entrepreneur and one of Nano Dimension (NNDM) Co-Founders.

Given that Nano Dimension provides 3D printing technology as a product and service, this firm can easily carve itself into a specialized market as other 3D printing companies do the same. There is absolutely no additional time than now for NNDM stock to capitalize on the current circumstances and make substantial strides forward as a solid long-term investment choice.

Two Israeli cybersecurity companies gained momentum over the past month over apparent cyberattack fear.

Cyren Ltd. (CYRN), provider of email security and threat intelligence solution, jumped yesterday more than 30% running from $2.2 at its lowest last month to more than $11 at its peak with 280% increase over the last month. Pre- market at $6.4.

Safe-T Group (SFET) global provider of cybersecurity and privacy solutions to consumers and enterprises, with 56% increase in the last months, breaking the 1$ mark last week. Safe-T estimated revenues for 2021 at $10 million, increase of over 100%.

Between Ukraine- Russia conflict and fear for cyberattacks from the Russian side and the latest Iranian attack on government websites, it seems that after a long numbness in cyber stocks, the get back to the center stage and might provide more shining moments.

So, what is the story about it? This short video can explain why it is a game changer in the bio-tech market.

When patients are in respiratory distress, medical teams have three ways of treating them depending on the severity of each individual situation.

The simplest method is to offer oxygen via a mask to increase its flow. For patients in more distress, intubation forms the second possibility. A mechanical ventilator — an Extracorporeal Membrane Oxygenation (ECMO) — is the third option and a last resort when all else has failed.

The ECMO, which can also be used in open-heart surgery to allow patients to remain awake, essentially acts as an exterior heart and lungs allowing for oxygenation of the red blood cells and the removal of carbon dioxide.

Inspira wants to inject an additional stage into possible respiratory treatment with a medical device that doesn’t require intubation and mimics much of the same treatment ECMO provides but in a much more compact and easier-to-operate form. It could be used if the oxygen face mask option fails and would not be seen as a salvage treatment, unlike the ECMO.

Inspira states that the ART device, given its size and relative ease of use, does not require multiple experienced medical personnel to operate it like the ECMO does, keeps people off expensive ventilators, protects them from possible complications, and could be used in far more service centers than the bulky ECMO machine.

Inspira’s approach to eventually gain regulatory approval for the ART device is to first introduce its own version of the ECMO machine, the Extracorporeal Life Support (ECLS), for approval. Offering a similar version of a machine that has already been approved in some cases by the U.S. Food and Drug Administration strengthens Inspira’s hand by heightening its profile.

For conclusion, the potential for Inspira’s respiratory technology to disrupt a multi-billion-dollar market is dependent on having an in-depth understanding of the unmet medical need and growing market.

Inspira’s product is currently in a developmental stage and has not yet been tested or used in humans and has not been cleared/approved by the U.S. Food and Drug Administration (FDA).

After a few raff months for cyber stocks, yesterday the shined bright at a sea of red. The conflict has prompted concerns of cyberattacks, especially against critical infrastructure companies and investor reacted fast.

Most cyber stocks, big and small, jumped in double digits:  Telos, up more than 20%; Palo Alto Networks, up 13%; CrowdStrike, up 13%; and Mandiant up 12%, SentinelOne 14%.

Under the radar cyber stocks

Under-the-radar small cap shares gained even more, the most noticeable was Cyren Ltd. (CYRN) that jumped more than 118% continue momentum on premarket with more than 30% increase and unusual volumes. Cyren investors knew a lot of disappointment this past year as share went from $18 to under $3 going through reverse split and down round investment.

Safe-T Group (NASDAQ:SFET)

Another under-the-radar share to notice in Safe-T Group (SFET). Another share that shown weakness lately, especially since going under $1. SFET went up more than 18% yesterday on Russia-Ukraine conflict rally. Safe-T estimated revenues for 2021 at $10 million, increase of over 100%. Recently, Dawson James analyst Jason Kolbert initiates coverage on Safe-T Group with a Buy rating and a price target of $6.00.

Uncomfortable as it is, conflicts and wars tend to create opportunities in unexpected sectors alongside markets volatility.

Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that as part of its highly attended “Psychedelics for Alcoholism” event series it will host market analyst Marissa Wright at a virtual event for investors.

The online event will be held on February 23, 2022 at 12 p.m. EST and is open and free to all, Registration is required. Clearmind’s last webinar attracted more than 1200 viewers.

“Psychedelics for Alcoholism” Investor Deep Dive will provide investors a broad overview of the psychedelic treatments market with an emphasis on alcohol use disorders.

Wright is a consultant on business strategy, market analysis, and new market entry for global firms. Based in Vancouver, Canada, she has 40 years of experience as an entrepreneur across a wide range of industries in North America and is an active member of Keiretsu Forum, the world’s largest early-stage angel investor network.

“As an innovative public company with a significant IP portfolio operating in an exciting and relatively new market, we want to provide investors a comprehensive review of the psychedelic treatment market and its potential,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind “The problem of alcoholism is only getting worse, with increased strain from the pandemic. Clearmind is working to bring long overdue relief and a new treatment in unique ways, and we look forward to highlighting some of the major reasons for our decision to pursue alcoholism indication as our first indication.”

The event will be hosted by Shannon Smadella, former Miss Canada & Spokesperson for World Psychedelics Day, and will feature Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.

To learn more about Psychedelics for Alcoholism, visit the event website.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:

Investor Relations,

Email: invest@clearmindmedicine.com Telephone: (604) 260-1566

General Inquiries, Info@Clearmindmedicine.com www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

If you want the short version- it is a target price of $20 a share, following recent updates, Nasdaq uplisting and discuss of an attractive setup.

Background:

SPRC recently uplisted to Nasdaq for OTC Markets. The current market cap is approx. $14 million with 2.3 million outstanding shares.

Summary and updates according to Aegis: SciSparc is a clinical-stage biotechnology company developing cannabinoid-based therapeutics. The company’s lead asset, SCI-110 (synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette syndrome (TS) (phase 2b) and Alzheimer’s disease (AD) and agitation (phase 2a). Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist) for pain. The company’s achievements in 2021 included preparing to enter mid-stage studies with SCI-110, publishing key data underpinning the efficacy of its programs, garnering additional IP protection, bolstering the balance sheet with successful capital markets activities, and uplisting to the Nasdaq exchange.

Clinical studies: SciSparc has prepared SCI-110 for a phase 2b study in TS, including arranging Dr. Kirsten Mueller-Vahl from Hanover Medical School as the study lead, engaging a contract research organization (CRO), and establishing the supply chain for drug manufacture. Additionally, SCI-110 has been prepared to enter a phase 2a study in AD and agitation, including receiving approval from the Israeli Ministry of Health (MOH) and Helsinki Committee, and engaging The Israeli Medical Center for Alzheimer’s to conduct the study. In 2021, SciSparc made progress on its earlier-stage assets as well, including entering an agreement with The Sheba Fund for Health Services and Research, to perform a preclinical study for SCI-210 and announcing positive topline results in a controlled preclinical trial on neuropathic and post-operative pain for SCI-160.

Cannabinoid-based therapeutics: The cannabinoid therapeutics class is still in the early innings, as we see it. The $7.2bn acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals (JAZZ; NR) offers an attractive precedent, on the back of meaningful revenue creation from the therapeutic use of cannabinoids. GW Pharma’s Epidiolex, indicated for the treatment of seizures associated with certain rare diseases, produced over $510mm of revenue in 2020, a strong indicator of the revenue potential in this emerging class.

SciSparc has constructed an attractive pipeline of therapeutics leveraging the “entourage effect,” predicated on the synergy displayed among cannabinoids and other substances when co-administered. A study of SCI-110 in TS patients, conducted at the Department of Psychiatry and the Child Study Center at Yale University, demonstrated improvement in tic symptoms that was statistically significant within 1 week of starting treatment compared with baseline. Treatment with SCI-110 led to an average improvement in tic symptoms of more than 20%, or a 7-point decrease in the YGTSS score. In our view, SciSparc represents a compelling opportunity for investors given the strong phase 2 data in SCI-110 generated at Yale, multiple upcoming catalysts expected, and the appealing valuation which is disconnected, in our view, from the intrinsic value of the pipeline.

The Coin Nations Summit 2021 will take place on October 13th and 14th, bringing together key industry leaders from across the globe. The conference agenda will present a series of expert keynotes and interactive panel discussions exploring crypto, blockchain, as well as DeFi, CBDCs, NFT, and the future of the new world economy. Driven by the mission to empower crypto professionals and thought leaders, the event will provide a resourceful environment for attendees to explore the current opportunities and challenges inherent within the space.  

“Coin Nations Summit 2021 is inspired by the immense success of the Bitcoin 2021 Conference that was hosted in Miami in June and inspired by the Mayor of Miami, Francis X. Suarez,” said Nir Kouris, founder of Coin Nations. “Our upcoming event has received support from major global partners who participated in the Miami event. The Coin Nations Summit is an unprecedented extension of the typical conference scenario as we have created a true matchmaking service with our curated “Matchathon” smart AI-based platform; attendees will actively participate interactive discussions and join one-on-one virtual meetings. Coin Nations extends a warm welcome to all crypto and blockchain companies, DeFi initiatives and makers, VCs, investors, central banks, NFT creators, and all others involved in shaping this global economy.”

The free to attend event will showcase unparalleled industry knowledge and unique insights by elite industry speakers from crypto, fintech, blockchain and DeFi, wallets and exchanges. Presenters include AJ Shanley, Vice President, Crypto at Visa, Dante Disparte, Chief Strategy Officer and Head of Global Policy at Circle , Tim Draper, Venture capitalist, founder of Draper Associates, DFJ and the Draper Venture Network, a global network of venture capital funds, Kevin O’Leary, “Mr. Wonderful” in reality show “Shark Tank,” investor at WonderFi,; Raphael Tetro, SVP Merchant Services at Nuvei; Alex Mashinsky, founder and CEO of Celsius; and Moon Pay CEO, Ivan Soto-Wright. Along side leading Crypto, Blockchain and NFT companies as Dapper Labs its flagship NBA Top Shot, Coinbase, Crypto.com, FTX, eToro, Nifty’s, Bitcoin Magazine, Blockchain Association, CityCoins and investors in technology trends as web 3.0.

Coin Nations is a major supporter of the crypto and blockchain community and plans to create hybrid meetups, hackathons, and gatherings in global crypto hubs such as Miami, Tel Aviv, New York and other main global tech cities. A special Limited Edition NFT will be minted exclusively for the first time on the virtual summit and attendees will have the opportunity to get it.

For direct FREE RSVP, please visit https://next.brella.io/join/CoinNations2021, or visit the official LinkedIn Channel & Site: https://coinnations.com/.

About Coin Nations

Coin Nations is supported by powerful organizations including central banks and eminent industry dignitaries from regulators to government officials and policy makers. The organization has established partnerships with the top countries and innovation leaders paving the way in crypto and blockchain technology, such as the USA, Hong Kong, Singapore and Israel. Within these ‘Blockchain Bridges’, agreements can be made on accelerating licensing processes and the exchange of information as well ‘best practices’ executed at policy and supervision level.

At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer energy wirelessly from the robot to the vehicle. The robotic platform is small enough to fit under the vehicle, it automatically positions itself for maximum efficiency charging and returns to its docking station at the end of the charging operation.

In July 2021, Charging Robotics has concluded a proof of concept, successfully demonstrating the capabilities of its electric vehicle wireless charging robot

Charging Robotics mission is to overcome one of today’s biggest challenges in wireless charging of electric vehicles-seamless, highly efficient battery charging for both manned and unmanned vehicles

The robotic platform carries an energy transmitting coil, batteries and supporting electronics. The second component of the system is an EV simulating unit, which houses the target batteries to be charged, an energy receiving coil and the supporting electronics. The robot navigates from its home position along a predefined route to the starting position, which is a point close to the optimal charging position. Charging occurs at the maximum rate when both coils are perfectly aligned. Following arrival to the starting position, the alignment process begins. As the energy was transmitted from the Robot transmitting coil to the receiving coil, the robot was ordered to move in small increments in order to optimize the charging rate.

The whole process demonstrated a charging efficiency of 93% at a power of 1kW and was capable of reaching the starting position as well as completing the alignment process. At no time did any part of the system come in physical contact with the other. Coils were positioned about 5 cm apart, and the robot ensured good alignment between them.

Following the successful POC, Charging Robotics plans to move forward with a commercial pilot project and to enhance